BOSTON, Aug. 27 The Center for Business Intelligence (CBI), a division of Advanstar Communications, is pleased to announce their full agenda for the 3rd Annual Bio/Pharmaceutical Collaboration and Transaction Accounting. Over 60 firms are already confirmed to gather in Philadelphia on September 22nd for this one-day seminar to hear expert insights and discuss industry case examples for accounting for collaborations and transactions. Perspectives on FASB, IFRS and US GAAP, plus updates on the impact of EITF 07-1, EITF 99-19, EITF 00-21, EITF 07-3 and EITF 08-A will be presented.
The FASB and SEC are considering refinements to the collaboration accounting model. This, coupled with the trend of IFRS convergence, make it critical that life science companies master the financial accounting and reporting of deal-making activities. Amidst changing regulations, top executives from companies such as Goldman Sachs, FASB, GlaxoSmithKline, Infinity Pharmaceuticals and Johnson & Johnson will examine:
If you would like to view the full agenda, please visit this page. A "best-in-class" reputation, CPE credits and professional networking make this an extremely worthwhile event. For more information on this event, please visit http://www.cbinet.com/collaboration. If you would like to apply for a press pass, please contact Erica Kirwan of CBI at 339.298.2263.
A subsidiary of Advanstar Communications, CBI Research, Inc. offers Pharmaceutical and Healthcare conferences that serve senior executives and government officials by providing a unique platform for highly focused content and ideal networking opportunities with senior policy- and decision-makers. CBI events provide you with concrete, real-life examples that you can begin to apply at your organization immediately for significant impact on costs and revenue. For more information, please visit http://www.cbinet.com.
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
-- Recent Mergers and Acquisitions Impacting the Pharmaceutical Sector -- Examples of Exotic Financings in Life Sciences -- Trends in Deal Values and Economic Factors in Assessing and Valuing Innovation -- Milestones and Revenue Arrangements with Multiple Deliverables -- EITF Updates on Revenue Recognition and Capitalization of Milestone Payments -- Considerations from a JFC Perspective for Joint Steering Committees (JSCs) and Other Joint Collaboration Meetings -- FASB Accounting Guidelines for Collaborative Arrangements and Revenue Recognition
SOURCE Center for Business Intelligence